BioCentury's websites will be down for upgrades starting at 11 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Jan 17, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Status

SB-509: Completed Phase IIb enrollment

Sangamo completed enrollment of 170 patients in the double-blind, placebo-controlled, U.S. Phase IIb SB-509-901 trial to evaluate intramuscular injections of SB-509. The Juvenile Diabetes Research Foundation International (

Read the full 122 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >